JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:1108-1116, doi:10.1016/j.jacc.2005.10.064 (Published online 21 February 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (34)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zoungas, S.
Right arrow Articles by McNeil, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zoungas, S.
Right arrow Articles by McNeil, J. J.

Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure

A Multicenter, Randomized, Controlled Trial

Sophia Zoungas, MBBS*, Barry P. McGrath, MBBS, MD*,*, Pauline Branley, BMed, PhD{dagger}, Peter G. Kerr, MBBS, PhD{ddagger}, Christine Muske, BSci(Nurs){dagger}, Rory Wolfe, PhD{dagger}, Robert C. Atkins, MBBS, DSc{ddagger}, Kathy Nicholls, MBBS, MD§, Margaret Fraenkel, BMBS, PhD||, Brian G. Hutchison, MBBS, Robert Walker, MBChB, MD# and John J. McNeil, MBBS, PhD{dagger}

* Department of Vascular Sciences and Medicine, Centre for Vascular Health, Monash University, Dandenong Hospital, Dandenong, Victoria, Australia
{dagger} Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
{ddagger} Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
§ Department of Nephrology, Royal Melbourne Hospital, Parkville, and Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
|| Department of Nephrology, Austin Health, Heidelberg, Victoria, Australia
Department of Nephrology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
# Department of Nephrology, Dunedin Hospital, Dunedin, New Zealand


Figure 1
View larger version (25K):

[in a new window]
  		Figure 1 Trial profile.

 

Figure 2
View larger version (26K):

[in a new window]
  		Figure 2 Mean total plasma homocysteine levels (bars = ±1 standard deviation) over time, by treatment group. The p value is for treatment effect from analysis of covariance on homocysteine at median follow-up (3.6 years) adjusted for baseline homocysteine.

 

Figure 3
View larger version (21K):

[in a new window]
  		Figure 3 Survival to first myocardial infarction, stroke, or cardiovascular death by treatment group. Red line = folic acid group; black line = placebo group.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.